Last updated: 11/03/2018 13:44:12
Repeat Dose Safety Study for Compound to Treat Anemia
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeat Oral Doses of 1278863A in Healthy Subjects
Trial description: The purpose of this study is to characterize the safety and tolerability of repeat doses of compound 1278863A in healthy subjects.
Primary purpose:
Basic Science
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
adverse events reporting
Timeframe: throughout study
Safety Labs (hematology)
Timeframe: Screening, Days -1, 1-3, 5, 7, 9, 11, 14-18, 21, 25, 28
vital signs (blood pressure and heart rate)
Timeframe: Days 1-15, 28
12-lead ECG
Timeframe: Screening, Days 1-2, 4, 6, 8, 10, 12, 14, 28
dual-lead cardiac monitoring (telemetry monitoring)
Timeframe: Days -1 to 3, 14
clinical monitoring/observation
Timeframe: throughout
Safety Labs (Chemistry)
Timeframe: Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
Safety Labs (Urinalysis)
Timeframe: Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
Secondary outcomes:
AUC(0-∞) on Day 1, AUC(0-τ), Cmax, tmax and t1/2, on Days 1 and 14
Timeframe: Days 1-2, 4, 6, 8, 10, 12, 14-18
Trough plasma concentrations at the end of the dosing interval
Timeframe: Days 2, 4, 6, 8, 10 and 12
Hemoglobin actual values, rate of rise, maximum change from baseline, and rate of decline following stopping of dosing
Timeframe: Days 1, 7, 14, 21, 28
Fetal hemoglobin actual values, change from baseline, and percent of total hemoglobin
Timeframe: Days 1, 7, 14, 21, 28
Actual values and change from baseline in erythropoietin
Timeframe: Days 1-4, 7, 14-15, 18, 21
Actual values and change from baseline in absolute VEGF
Timeframe: Days 1-2, 14-15, 18, 21
Actual values and change from baseline in hepcidin
Timeframe: Days 1-2, 7, 14-15, 18, 21
Actual values and change from baseline in total iron binding capacity (TIBC)
Timeframe: Screening, Days 1, 7, 14, 18, 21
Actual values and change from baseline in transferring saturation (%)
Timeframe: Days 1, 7, 14, 18, 21
Interventions:
Enrollment:
24
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Kidney Disease
Product
daprodustat
Collaborators
Not applicable
Study date(s)
March 2009 to September 2009
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 55 years
Accepts healthy volunteers
Yes
- 1. Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- 2. Male or female between 18 and 55 years of age, inclusive.
- 1. The subject has a positive pre-study drug screen.
- 2. A hemoglobin value at screening is:
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. 2. Male or female between 18 and 55 years of age, inclusive. 3. A female subject must be of non-childbearing potential. 4. Male subjects must agree to use one of the acceptable contraception methods listed in the protocol 5. Body weight greater than or equal to 50 kg and BMI within the range 19
- 31 kg/m2 (inclusive). 6. Capable of giving written informed consent 7. QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion criteria:
- 1. The subject has a positive pre-study drug screen. 2. A hemoglobin value at screening is:
- Male subjects or post-menopausal females: > 15.5 g/dL
- Female subjects: > 14.5 g/dL 3. The values of hematological parameters at screening are: MCV: outside the reference range and clinically significant deemed by the investigator and GSK Medical Monitor 4. The values of the following tests at screening are:
- TIBC: outside the reference range
- Serum iron: outside the reference range
- Serum ferritin: outside the reference range 5. A value at screening is greater than the upper limit of reference range for the following clinical laboratory parameters: AST, ALT, direct bilirubin. 6. Clinically significant abnormal CPK determined by the investigator and GSK Medical Monitor. 7. Calculated creatinine clearance: < 60mL/min 8. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening. 9. A positive test for HIV antibody. 10. History of drug abuse or dependence within 6 months of the study. 11. History of regular alcohol consumption within 6 months of the study 12. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. 13. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug 14. History of sensitivity to any of the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. 15. History of sensitivity to heparin or heparin-induced thrombocytopenia. (if the clinical research unit uses heparin to maintain intravenous cannula patency) 16. Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of the study drugs. 17. History of peptic ulcer disease. 18. History of malignancy tumor. Non-melanoma skin cancer that has been definitely removed is allowed. 19. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing. 20. Lactating females. 21. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. 22. Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol. 23. Consumption of red wine, seville oranges, grapefruit or grapefruit juice, exotic citrus fruits, grapefruit hybrids or fruit juices of the prohibited fruits from 7 days prior to the first dose of study medication 24. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). 25. Exposure to more than four new chemical entities within 12 months prior to the first dosing day. 26. Subject is mentally or legally incapacitated.
Trial location(s)
Location
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
Status
Terminated/Withdrawn
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2009-02-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 112842 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website